Relmada Therapeutics (RLMD) Begins Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with MDD - StreetInsider.com

Submitted by Anonymous (not verified) on Thu, 04/01/2021 - 12:12

Relmada Therapeutics (RLMD) Begins Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with MDD  StreetInsider.com